Key Takeaways
- HIMS shares climb 7% in Thursday’s premarket session, building on Wednesday’s 10% advance and marking a fourth consecutive day of positive momentum
- The telehealth company’s stock has skyrocketed 64% over the past week — representing its strongest weekly gain in company history
- A landmark partnership with Novo Nordisk enables HIMS to distribute FDA-cleared Ozempic and Wegovy through its digital platform, triggering the rally
- Wall Street responded with enthusiasm: Barclays boosted its target to $29 from $25 (overweight rating), while Bank of America upgraded shares from underperform to neutral with a $23 target
- Fourth-quarter earnings per share reached $0.08, crushing the Street’s $0.02 forecast, while revenue of $617.8M came marginally below the $619.5M estimate
Hims & Hers Health (HIMS) is experiencing a transformative week that investors will remember for years. Shares advanced approximately 7% during Thursday’s premarket hours, building momentum after Wednesday’s impressive 10% rally. This streak now extends to four consecutive trading sessions in the green.
Hims & Hers Health, Inc., HIMS
As of Wednesday’s closing bell, HIMS has posted a remarkable 64% weekly gain. This represents the company’s strongest weekly performance since going public.
The catalyst for this explosive move emerged Monday when the telehealth platform announced a groundbreaking partnership with Novo Nordisk for weight-loss medication distribution. This agreement effectively removes a significant legal uncertainty that had been weighing on investor sentiment.
The collaboration allows Hims & Hers to offer FDA-cleared Ozempic and Wegovy medications directly to consumers via its digital healthcare ecosystem. Wall Street analysts are viewing this development as a significant catalyst for both top-line growth and profit margin expansion.
During Wednesday’s trading session, HIMS changed hands at $26.17, representing a $2.70 gain. Trading volume reached 51.6 million shares — substantially higher than the typical 33.3 million daily average.
Wall Street Raises Price Targets
The Novo Nordisk announcement prompted several investment firms to reassess their outlook on the stock. Barclays increased its price objective from $25 to $29 while maintaining an overweight recommendation. This target suggests approximately 10.8% potential appreciation from recent trading levels.
Bank of America made a more dramatic shift, upgrading HIMS from underperform to neutral and raising its price target from $12.50 to $23. Deutsche Bank also joined the action, lifting its target to $28 from $25 while keeping a hold rating in place.
According to MarketBeat’s aggregated analyst data, the consensus rating stands at Hold with an average price target of $30.75. The breakdown includes three Buy recommendations, thirteen Hold ratings, and one Sell opinion.
Options market activity also reflected heightened bullish sentiment, with approximately 322,000 call contracts changing hands — an unusually elevated level suggesting traders are positioning for continued upward movement.
Strong Q4 Results and Capital Allocation
HIMS unveiled its fourth-quarter financial results on February 23. Earnings per share of $0.08 handily exceeded Wall Street’s $0.02 projection. Revenue totaled $617.8 million, falling just short of the $619.5 million analyst consensus.
Despite the minor revenue miss, top-line growth remained robust at 28.4% compared to the prior-year period. The company delivered a 22.48% return on equity alongside a net margin of 5.47%.
Management also announced authorization for a $250 million share repurchase program, representing roughly 3% of outstanding shares. Share buyback programs generally indicate that company leadership views current valuations as attractive.
For the full fiscal year ahead, Wall Street is projecting earnings per share of $0.29.
The stock’s 52-week trading range spans from $13.74 to $70.43. At Wednesday’s close, shares traded comfortably above the 50-day moving average of $24.31, though still trailing the 200-day moving average of $37.75.
Even after this week’s substantial gains, short interest remains worth monitoring. Analysts have noted that short squeeze dynamics could contribute to volatility — price movements fueled by forced short covering can reverse sharply when speculative momentum subsides.
Institutional ownership currently represents 63.52% of outstanding HIMS stock. Company insiders control 17.71%, though insider selling totaled 80,463 shares during the most recent quarter.
